Aspira Pathlab & Diagnostics Ltd: Intrinsic Value & Share Price Analysis

GETAKA RESEARCH Company fundamentals

The investment picture

Understand the business. Put the price in context.

Stored data · Not a live quote

Share price₹130.00Price record: 24 September 2026, 10:45 pm +05:30

Model valuation₹14.56Overvalued · 7 models

Return on capital2.84%ROCE · Latest stored basic data

Earnings multipleNot availableP/E · Compare with similar businesses

VALUATION CONTEXT

The model estimate is 88.8% below the stored share price. Strong operating metrics can still come at a demanding price.

Explore the models

LATEST QUARTER

Revenue

-5.4%

Dec 2025 vs Dec 2024

Reported revenue: ₹5 Cr

LATEST QUARTER

Net profit

Moved to a loss

Dec 2025 vs Dec 2024

Reported net profit: ₹-2 Cr

EARNINGS CHECK

Profit into cash

0.91×

Operating cash flow / net profit

Matched annual period: Mar 2025

₹0.91 of operating cash for each ₹1 of reported profit.

WHAT TO WATCH

Check the latest filings, margin changes and cash generation before drawing conclusions from the headline score.

View financials

Reporting gap · Check newer company filings

Annual: Mar 2025 · Quarterly: Dec 2025 · Cash flow: Mar 2026. These sections refresh independently. A recent price update does not mean the financial statements are current.

Sources: Company data source. Check the company filings linked by the source for the reporting basis and exceptional items.

CONNECT THE NUMBERS

What the numbers reveal

Growth, cash and resilience — with the evidence behind each measure.

5 measures available

Quarterly net margin

-30.47%

-37.49 pp year on year

Each ₹100 of revenue produced ₹-30.47 of reported net profit. Compare the change with tax and other-income movements.

Dec 2025 vs Dec 2024

Calculation & source

Net profit ÷ revenue × 100. Change is in percentage points (pp), not percent growth.

Current: ₹-1.56 Cr profit / ₹5.12 Cr revenue. Prior: ₹0.38 Cr / ₹5.41 Cr.

View source table

Revenue momentum gap

-26.26pp

Latest quarter -5.4% · trailing year +20.9%

The latest quarter grew more slowly than the four-quarter trend. This comparison describes momentum; it does not predict the next quarter.

Eight consecutive quarters ending Dec 2025

Calculation & source

Latest-quarter revenue YoY growth minus revenue growth of the latest four quarters against the preceding four.

Latest quarter: ₹5.12 Cr vs ₹5.41 Cr. Four-quarter totals: ₹24.24 Cr vs ₹20.05 Cr.

View source table

Interest coverage

6.94×

Earnings before interest and tax / interest

Reported earnings before interest and tax cover the interest expense 6.9 times. Other income is included; principal repayments are not.

Mar 2025 · annual P&L

Calculation & source

(Profit before tax + interest expense) ÷ interest expense.

Profit before tax: ₹2.08 Cr. Interest: ₹0.35 Cr.

View source table

Borrowings / book equity

0.27×

₹27.15 borrowed per ₹100 of equity

This compares reported borrowings with equity capital plus reserves. It is gross borrowing, not net debt; reserves are not cash.

Mar 2026 · balance sheet

Calculation & source

Borrowings ÷ (equity capital + reserves), from the same balance-sheet date.

Borrowings: ₹3.32 Cr. Equity capital: ₹10.29 Cr. Reserves: ₹1.94 Cr.

View source table

Cash cycle change

-7days

16 days now · 23 days before

A shorter cycle can reduce the time cash is tied up in operations. A longer supplier-payment period can also shorten it, so read the components.

Mar 2025 vs Mar 2024

Calculation & source

Cash cycle = debtor days + inventory days − payable days. Change = current cycle − prior-year cycle.

Current: 38.99 + 50.31 − 73 days. Prior: 61.94 + 62.69 − 101.7 days.

View source table

1 measures unavailable — see missing inputs

Cash backing needs three consecutive matching years, with positive profit in each year.

The earnings-growth scenario needs a positive, usable P/E. It is not shown for missing or loss-based P/E figures.

Periods are matched within each calculation; different measures may use different reporting dates. Derived from the stored tables, not live filings. Check the source reporting basis before comparing companies. About ratio analysis.

Valuation models

₹0.60Overvalued · Model 99.54% below pricevs CMP ₹130.00

P/E (15.0) × ROE (0.7%) × BV (₹7.09) × 0.8 × (1 + dividend yield 2.00%)

Defaults: P/E=15

₹14.56Overvalued · Model 88.80% below pricevs CMP ₹130.00

Margin of safety: -792.9% (Negative)Model agreement score: 63/100 (Moderate)Models: All 7: Overvalued

Model	Category	Value	Weight	Signal
PE-ROE	Earnings	₹0.48	24%	Over (-99.6%)
Graham Number	Earnings	₹15.10	18%	Over (-88.4%)
DCF	Cash Flow	₹10.84	18%	Over (-91.7%)
Net Asset Value	Assets	₹11.86	10%	Over (-90.9%)
EV/EBITDA	Enterprise	₹45.77	12%	Over (-64.8%)
Earnings Yield	Earnings	₹14.30	10%	Over (-89%)
Revenue Multiple	Revenue	₹21.34	7%	Over (-83.6%)
Consensus (7 models)		₹14.56	100%	Overvalued

Key Drivers: EPS CAGR -19.9% drags value — could be higher if earnings stabilize. | ROE 0.7% is below cost of equity.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -19.9% · Defaults: P/E=15

Margin of safety = (model value − price) ÷ model value. The agreement score is a heuristic based on model count, direction and spread; it is not a probability of accuracy. These models are estimates, not price targets.

Estimates depend on assumptions. Compare the model range and verify fresh filings.

Analysis summary

Data coverage: Price-data record updated 24 September 2026, 10:45 pm +05:30. Annual results through Mar 2025; quarterly results through Dec 2025; cash flow through Mar 2026. Each section can have a different reporting period. The share price is not live.

Valuation in context

Operating performance

Revenue for Mar 2025 was ₹22.00 Cr, versus ₹13.20 Cr in Mar 2024 (66.7% year on year). Net profit for Mar 2025 was ₹2.07 Cr, versus ₹-2.67 Cr in Mar 2024 (a return to profit). These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.

Cash generation

For the same Mar 2025 period, operating cash flow was ₹1.88 Cr against net profit of ₹2.07 Cr. Cash flow covered 0.91 times reported profit. Cash generation supports the reported profit for this period; check whether this continues over several years.

Balance-sheet check

Reported borrowings were ₹3.32 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.

How to use the valuation and peer comparisons

The Intrinsic Value panel combines the available model estimates using the displayed weights. Earnings, cash-flow, dividend and asset-based methods can give very different answers. The displayed 12% cost of equity and 4% terminal growth assumptions apply where relevant; historical EPS growth is not a promise of future growth. Use the individual values and their spread to judge sensitivity.

The peer group follows the stored industry classification and may include different business models. Compare reporting periods, leverage and recurring earnings before interpreting a valuation gap. For banks and other financial businesses, capital adequacy and asset quality can be more informative than industrial-company cash-flow ratios.

Sources: Company data source. Check the company filings linked by the source for the reporting basis and exceptional items.

Automatically generated interpretation of the stored financial data, not a separately researched analyst opinion. Missing data is not evidence of poor performance. New filings become available here after the existing data refresh process captures them.

Business quality

Aspira Pathlab & Diagnostics Ltd scores 52/100 (Average)

Fundamental screening score · A strong business is not automatically an attractively priced stock.

Data coverage: 5/5 dimensions. Financial reporting periods vary by section.

Stock Health46/100 · Moderate

ROCE 2.8% WeakROE 0.7% WeakDebt/equity Not availableInterest Coverage 11.3x StrongProfitable 3/5 available years Reported history

Ownership Trends60/100 · Moderate

Promoter increased by 28.19 pp Share increased

Earnings Quality50/100 · Moderate

OPM contracting (22% → 4%) DecliningWorking capital: 14 days (improving) Efficient

Quarterly Momentum80/100 · Strong

Revenue (4Q): +21% YoY AcceleratingProfit (4Q): +73% YoY StrongOPM: -23.6% (down 37.7% YoY) Margin pressure

Peer Comparison25/100 · Weak

ROCE 2.8% vs industry 12.4% Below peersROE 0.7% vs industry 10.7% Below peers3Y sales CAGR: 4% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Peer Comparison 15% · Ownership Trends 10%. Scores use stored reporting periods and are screening indicators, not investment recommendations. Missing dimensions are excluded and the remaining weights are rescaled. At least three dimensions are required for an overall score. Holding movements describe ownership shares, not proven trading flows. Broad industry groups and financial-sector accounting can limit comparability.

Share Price and Basic Stock Data

Last Updated: September 24, 2026, 10:45 pm

Market Cap	134 Cr.
Current Price	130
Intrinsic Value	₹14.56
High / Low	139/49.0
Stock P/E
Book Value	7.09
Dividend Yield	0.00 %
ROCE	2.84 %
ROE	0.69 %
Face Value	10.0
PEG Ratio	0.00

Understand these figures: how to read the P/E ratio, ROE versus earnings per share, and calculate intrinsic value.

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Aspira Pathlab & Diagnostics Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Aspira Pathlab & Diagnostics Ltd	134 Cr.	130	139/49.0		7.09	0.00 %	2.84 %	0.69 %	10.0
Aashka Hospitals Ltd	207 Cr.	88.5	99.5/59.0	72.9	44.1	0.00 %	4.05 %	2.80 %	10.0
Lotus Eye Hospital & Institute Ltd	239 Cr.	115	153/97.6	1,496	28.9	0.00 %	1.41 %	0.13 %	10.0
Asarfi Hospital Ltd	349 Cr.	177	257/123	19.2	52.2	0.00 %	18.8 %	19.0 %	10.0
Shalby Ltd	1,589 Cr.	147	273/126	40.4	93.1	0.00 %	6.12 %	2.45 %	10.0
Industry Average	27,785.94 Cr	738.48		157.93	85.95	0.31%	11.88%	11.00%	9.19

All Competitor Stocks of Aspira Pathlab & Diagnostics Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	4.37	3.41	2.60	3.32	3.46	3.82	4.64	6.18	5.41	5.78	5.25	8.09	5.12
Expenses	3.56	3.26	2.92	3.68	3.83	3.95	4.29	4.83	4.65	4.73	4.44	5.90	6.33
Operating Profit	0.81	0.15	-0.32	-0.36	-0.37	-0.13	0.35	1.35	0.76	1.05	0.81	2.19	-1.21
OPM %	18.54%	4.40%	-12.31%	-10.84%	-10.69%	-3.40%	7.54%	21.84%	14.05%	18.17%	15.43%	27.07%	-23.63%
Other Income	0.12	0.07	0.10	0.14	0.10	0.08	0.09	0.08	0.09	0.13	0.11	0.14	0.13
Interest	0.10	0.10	0.10	0.10	0.09	0.08	0.08	0.08	0.09	0.09	0.09	0.10	0.10
Depreciation	0.39	0.38	0.39	0.39	0.38	0.38	0.38	0.36	0.39	0.37	0.37	0.40	0.38
Profit before tax	0.44	-0.26	-0.71	-0.71	-0.74	-0.51	-0.02	0.99	0.37	0.72	0.46	1.83	-1.56
Tax %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Profit	0.44	-0.26	-0.72	-0.71	-0.74	-0.50	-0.02	0.99	0.38	0.72	0.47	1.84	-1.56
EPS in Rs	0.43	-0.25	-0.70	-0.69	-0.72	-0.49	-0.02	0.96	0.37	0.70	0.46	1.79	-1.52

Last Updated: March 3, 2026, 12:08 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 11:05 pm

Metric	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	0.00	0.00	0.00	0.76	4.36	7.64	8.42	15.21	19.54	14.46	13.20	22.00	24.24
Expenses	0.02	0.14	0.23	3.34	8.24	10.88	10.25	11.69	13.16	12.86	14.38	18.44	21.40
Operating Profit	-0.02	-0.14	-0.23	-2.58	-3.88	-3.24	-1.83	3.52	6.38	1.60	-1.18	3.56	2.84
OPM %				-339.47%	-88.99%	-42.41%	-21.73%	23.14%	32.65%	11.07%	-8.94%	16.18%	11.72%
Other Income	0.02	0.21	0.32	0.31	0.22	0.25	0.29	0.20	0.09	0.32	0.42	0.36	0.51
Interest	0.00	0.00	0.05	0.26	0.80	0.96	1.01	0.89	0.37	0.42	0.37	0.35	0.38
Depreciation	0.00	0.00	0.00	0.20	1.12	1.23	1.66	1.44	1.64	1.59	1.54	1.49	1.52
Profit before tax	0.00	0.07	0.04	-2.73	-5.58	-5.18	-4.21	1.39	4.46	-0.09	-2.67	2.08	1.45
Tax %		57.14%	25.00%	0.00%	0.00%	0.00%	0.71%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Profit	0.00	0.02	0.03	-2.72	-5.58	-5.18	-4.24	1.38	4.46	-0.09	-2.67	2.07	1.47
EPS in Rs	0.00	0.09	0.13	-5.24	-10.75	-6.32	-4.56	1.34	4.33	-0.09	-2.59	2.01	1.43
Dividend Payout %		0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	50.00%	-9166.67%	-105.15%	7.17%	18.15%	132.55%	223.19%	-102.02%	-2866.67%	177.53%
Change in YoY Net Profit Growth (%)	0.00%	-9216.67%	9061.52%	112.32%	10.98%	114.40%	90.64%	-325.21%	-2764.65%	3044.19%

Aspira Pathlab & Diagnostics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	21%
3 Years:	4%
TTM:	48%

Compounded Profit Growth
10 Years:	59%
5 Years:	20%
3 Years:	-23%
TTM:	230%

Stock Price CAGR
10 Years:	%
5 Years:	26%
3 Years:	13%
1 Year:	99%

Return on Equity
10 Years:	%
5 Years:	17%
3 Years:	-3%
Last Year:	24%

Last Updated: September 5, 2025, 2:26 pm

Balance Sheet

Last Updated: May 26, 2026, 4:00 am

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	2.25	2.25	5.19	5.19	8.19	9.29	10.29	10.29	10.29	10.29	10.29	10.29
Reserves	1.36	1.39	0.72	-4.86	-7.93	-10.42	-6.91	-2.43	-2.47	-5.08	-3.01	1.94
Borrowings	0.00	2.62	7.29	11.36	12.52	13.80	7.01	8.85	8.24	7.71	8.13	3.32
Other Liabilities	0.21	0.03	1.66	0.84	2.02	1.67	1.39	1.42	1.28	1.79	2.11	2.96
Total Liabilities	3.82	6.29	14.86	12.53	14.80	14.34	11.78	18.13	17.34	14.71	17.52	18.51
Fixed Assets	0.00	0.04	7.79	7.91	8.90	8.70	7.75	9.57	8.01	6.79	6.53	7.20
CWIP	0.00	0.00	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.13	0.00
Other Assets	3.82	6.25	6.82	4.62	5.90	5.64	4.03	8.56	9.33	7.92	10.86	11.31
Total Assets	3.82	6.29	14.86	12.53	14.80	14.34	11.78	18.13	17.34	14.71	17.52	18.51

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity +	-0.37	-1.29	-4.81	-3.39	-1.87	5.67	2.03	-0.01	1.05	1.88	1.45
Cash from Investing Activity +	-0.02	-10.14	-0.77	-1.97	0.24	-0.09	-0.51	0.16	0.14	0.07	-0.80
Cash from Financing Activity +	2.64	8.91	6.52	3.35	1.27	-2.17	-1.35	-0.94	-0.95	-0.99	-1.14
Net Cash Flow	2.25	-2.52	0.94	-2.00	-0.35	3.41	0.17	-0.79	0.24	0.95	-0.49
Free Cash Flow	-0.41	-8.41	-5.81	-3.90	-1.92	5.37	1.42	-0.15	0.79	1.71	0.75
CFO/OP	139%	50%	124%	105%	101%	161%	32%	-1%	-89%	53%	99%

Free Cash Flow

Free cash flow reported in the stored cash-flow statement (₹ Cr)
Period	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Free Cash Flow	N/A	-0.41	-8.41	-5.81	-3.90	-1.92	5.37	1.42	-0.15	0.79	1.71	0.75

This table and the chart use the Free Cash Flow row from the same stored cash-flow statement. Free cash flow generally measures operating cash flow after capital expenditure; check the source definition and reporting basis. It is not operating profit minus borrowings.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2012	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days			43.22	29.30	38.22	26.01	40.80	83.87	59.07	61.94	38.99
Inventory Days			312.86	103.88	45.22	51.36	51.35	46.50	58.40	62.69	50.31
Days Payable			730.00	64.58	46.84	73.37	91.60	70.91	51.10	101.70	73.00
Cash Conversion Cycle			-373.92	68.61	36.60	4.00	0.55	59.46	66.37	22.93	16.30
Working Capital Days			-2,199.61	-5.86	-96.03	-127.01	16.32	69.30	48.72	25.16	14.10
ROCE %	0.00%	1.82%	-25.39%	-38.41%	-34.49%	-25.15%	19.77%	35.65%	2.01%	-15.87%	17.37%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	18.90%	18.90%	18.72%	18.72%	18.55%	18.55%	18.39%	18.39%	18.39%	18.39%	18.39%	46.58%
Public	81.10%	81.10%	81.29%	81.28%	81.46%	81.46%	81.62%	81.62%	81.61%	81.61%	81.61%	53.41%
No. of Shareholders	1,406	1,351	1,512	1,695	1,706	1,593	1,741	1,770	1,755	1,784	1,769	1,620

Shareholding Pattern Chart

No. of Shareholders

Aspira Pathlab & Diagnostics Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24
FaceValue	10.00	10.00
Basic EPS (Rs.)	1.97	-2.60
Diluted EPS (Rs.)	1.97	-2.60
Cash EPS (Rs.)	3.46	-1.10
Book Value[Excl.RevalReserv]/Share (Rs.)	7.03	5.07
Book Value[Incl.RevalReserv]/Share (Rs.)	7.03	5.07
Revenue From Operations / Share (Rs.)	21.37	12.83
PBDIT / Share (Rs.)	3.80	-0.74
PBIT / Share (Rs.)	2.35	-2.24
PBT / Share (Rs.)	2.01	-2.60
Net Profit / Share (Rs.)	2.01	-2.60
NP After MI And SOA / Share (Rs.)	1.97	-2.60
PBDIT Margin (%)	17.79	-5.79
PBIT Margin (%)	11.00	-17.45
PBT Margin (%)	9.42	-20.23
Net Profit Margin (%)	9.42	-20.23
NP After MI And SOA Margin (%)	9.19	-20.23
Return on Networth / Equity (%)	27.94	-51.25
Return on Capital Employeed (%)	16.03	-18.23
Return On Assets (%)	11.58	-18.16
Asset Turnover Ratio (%)	1.37	0.00
Current Ratio (X)	2.26	2.10
Quick Ratio (X)	2.05	1.89
Inventory Turnover Ratio (X)	45.90	0.00
Interest Coverage Ratio (X)	11.27	-2.08
Interest Coverage Ratio (Post Tax) (X)	6.97	-6.27
Enterprise Value (Cr.)	86.79	31.60
EV / Net Operating Revenue (X)	3.95	2.39
EV / EBITDA (X)	22.18	-41.27
MarketCap / Net Operating Revenue (X)	3.99	2.42
Price / BV (X)	12.12	6.12
Price / Net Operating Revenue (X)	3.99	2.42
EarningsYield	0.02	-0.08

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Frequently asked questions

What is the intrinsic value of Aspira Pathlab & Diagnostics Ltd and is it undervalued?

Aspira Pathlab & Diagnostics Ltd: the stored intrinsic value estimate is ₹14.56, compared with a stored share price of ₹130.00. The model value is 88.8% below that quote. The model classifies this as overvalued; it is an estimate dependent on the inputs and assumptions, not a price target or a buy/sell recommendation. The estimate uses the available valuation models and weights shown in the Intrinsic Value panel, including earnings, cash-flow and asset-based approaches where data permits. It is not a P/E-only calculation.

What share price and 52-week range are shown for Aspira Pathlab & Diagnostics Ltd?

The stored share price is ₹130.00. Price-data record updated: 24 September 2026, 10:45 pm +05:30. This is not a live quote. The stored 52-week high / low is 139/49.0; this is a rolling range, not a financial-year range.

How have Aspira Pathlab & Diagnostics Ltd's revenue and profit changed?

Does Aspira Pathlab & Diagnostics Ltd's profit convert into cash?

What should I check in Aspira Pathlab & Diagnostics Ltd's balance sheet?

Reported borrowings were ₹3.32 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.

What could change Aspira Pathlab & Diagnostics Ltd's intrinsic value estimate?

Changes in sustainable earnings, cash generation, capital needs, debt and share count can change the estimate. The displayed model uses a 12% cost of equity and 4% terminal growth assumption where applicable. Higher discount rates or weaker growth generally reduce discounted values. Compare the individual model values and weights, and verify fresh filings before relying on the result.